Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H)

J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):800-2. doi: 10.1136/jnnp.2005.076869.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Drug Resistance
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / drug therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antirheumatic Agents
  • Immunoglobulins, Intravenous
  • Alemtuzumab